Alector Reports First Quarter 2025 Financial Results and Provides Business Update
- Extended cash runway into H2 2027 with $354.6M in cash and investments
- Completed enrollment ahead of schedule in PROGRESS-AD Phase 2 trial for AL101 in Alzheimer's
- On track for topline data from pivotal INFRONT-3 Phase 3 trial in Q4 2025
- Reduced R&D expenses by 25.7% YoY from $45.2M to $33.6M
- Revenue decreased significantly to $3.7M from $15.9M YoY
- Net loss increased to $40.5M from $36.1M YoY
- Loss per share increased to $0.41 from $0.38 YoY
Insights
Alector shows clinical progress toward Q4 2025 Phase 3 readout while extending cash runway to 2027, despite increased quarterly losses.
Alector's clinical pipeline continues to advance with key milestones progressing as scheduled. The INFRONT-3 Phase 3 trial of latozinemab in FTD-GRN remains the company's most promising near-term catalyst, with topline data expected in Q4 2025. This trial targets a genetically-defined frontotemporal dementia population where progranulin replacement through latozinemab's mechanism could potentially modify disease progression.
The completed enrollment in the PROGRESS-AD Phase 2 trial of AL101 in early Alzheimer's disease ahead of schedule demonstrates operational efficiency and could accelerate the development timeline. AL101 targets the same biological pathway as latozinemab (PGRN elevation through sortilin receptor antagonism) but has differentiated pharmacokinetic properties that make it more suitable for prevalent conditions like Alzheimer's.
Strategically, Alector is leveraging its proprietary Brain Carrier technology platform to deliver therapeutics across the blood-brain barrier, applying this to both emerging targets and genetically and pharmacologically validated targets like amyloid beta and GCase. While anti-amyloid approaches have now been validated clinically by competitors' successes, Alector's brain-penetrant approach could potentially improve efficacy or safety profiles compared to existing therapies.
The extension of cash runway into H2 2027 indicates prudent financial management and provides sufficient operational funding to reach critical value-inflection points, particularly the INFRONT-3 readout and potential subsequent regulatory submission if results are positive.
Alector's Q1 2025 financial results reveal a carefully managed balance sheet amid advancing clinical programs. The $354.6 million cash position supports operations into H2 2027, comfortably covering the critical INFRONT-3 Phase 3 readout in Q4 2025 and potential regulatory submission without immediate financing needs.
Revenue declined significantly to $3.7 million versus $15.9 million in Q1 2024, but this drop was anticipated due to the completion of performance obligations related to the AL002 program and latozinemab FTD-C9orf72 Phase 2 trial. This illustrates a common pattern in biotech collaboration accounting where revenue recognition doesn't necessarily reflect operational progress.
The 25.7
Net loss widened to $40.5 million ($0.41 per share) from $36.1 million ($0.38 per share), primarily driven by the expected revenue decline. The reaffirmed 2025 guidance shows management confidence in their financial projections despite the increased quarterly loss.
The cash runway extension represents effective financial stewardship, giving Alector substantial operational flexibility through multiple potential value-driving clinical readouts without immediate dilutive financing pressure. This financial stability positions the company favorably compared to many clinical-stage biotech peers facing more immediate funding constraints.
Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025
Completed enrollment in PROGRESS-AD Phase 2 clinical trial of AL101 in early Alzheimer’s disease
Continuing to pursue Alector Brain Carrier programs, including the company’s anti-amyloid beta antibody and its GCase enzyme replacement therapy
Extending runway into the second half of 2027, with
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today reported first quarter 2025 financial results and recent portfolio and business updates. As of March 31, 2025, Alector’s cash, cash equivalents, and investments totaled
"With cash runway extending into the second half of 2027, Alector is advancing a portfolio of drug candidates toward novel as well as validated targets for people living with neurodegenerative diseases," said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. "We remain on track to report topline results from the pivotal INFRONT-3 Phase 3 trial of latozinemab in frontotemporal dementia with a granulin gene mutation in the fourth quarter of 2025, and we have completed enrollment in the PROGRESS-AD Phase 2 trial of AL101/GSK4527226 in early Alzheimer’s disease. This progress reinforces our commitment to developing meaningful therapies for people living with neurodegeneration."
Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development at Alector, added, "We continue to strategically pursue our Alector Brain Carrier programs, which include our brain-penetrant antibody targeting amyloid beta for Alzheimer’s disease, and our engineered, brain-penetrant GCase enzyme replacement therapy for Parkinson’s disease. Both amyloid beta and GCase are genetically and pharmacologically validated targets. Together, our clinical, preclinical, and research pipeline positions Alector to address critical unmet needs in neurodegenerative diseases with first- and best-in-class therapeutic potential.”
Cash Runway Extension into the Second Half of 2027: Alector has extended its cash runway into the second half of 2027, supporting the continued advancement of its late-stage and preclinical portfolio. This includes completion of the pivotal INFRONT-3 Phase 3 trial of latozinemab and the ongoing execution of the PROGRESS-AD Phase 2 trial of AL101. It also encompasses the advancement of the company’s brain-penetrant anti-amyloid beta antibody and its brain-penetrant GCase enzyme replacement therapy.
Recent Clinical Updates
Progranulin Programs (latozinemab (AL001) and AL101/GSK4527226) Being Developed in Collaboration with GSK
Latozinemab
- The pivotal, randomized, double-blind, placebo-controlled INFRONT-3 Phase 3 clinical trial is ongoing. It evaluates the safety and efficacy of latozinemab in frontotemporal dementia with a granulin gene mutation (FTD-GRN). Alector and GSK remain on track to report topline data from the trial in the fourth quarter of 2025.
- The primary endpoint in INFRONT-3 is disease progression as measured by the Clinical Dementia Rating scale plus National Alzheimer’s Disease Coordinating Center Frontotemporal Lobar Degeneration Sum of Boxes (CDR® plus NACC FTLD-SB). The trial also assesses effects on progranulin (PGRN) levels and biomarkers of lysosomal function, inflammation, astrogliosis, and neurodegeneration.
- Latozinemab is a novel investigational human monoclonal antibody (mAb) designed to block and downregulate the sortilin receptor to elevate PGRN levels in the brain.
AL101/GSK4527226
- In April 2025, Alector and GSK completed enrollment ahead of schedule in PROGRESS-AD, a global, randomized, double-blind, placebo-controlled Phase 2 clinical trial evaluating AL101/GSK4527226 in early Alzheimer’s disease (AD).
- AL101/GSK4527226 is an investigational human mAb designed to block and downregulate the sortilin receptor to elevate the level of PGRN in the brain in a manner that is similar to investigational latozinemab but with different pharmacokinetic and pharmacodynamic properties, making it suitable for the potential treatment of more prevalent neurodegenerative diseases.
Preclinical and Research Pipeline
Alector continues to advance its preclinical and early research pipeline, selectively supported by Alector Brain Carrier (ABC), the company’s proprietary blood-brain barrier technology platform. ABC enables the targeted delivery of therapeutics to the brain and seeks to optimize safety and efficacy through its versatile and tunable design while facilitating the efficient and well-distributed transport of a wide variety of payloads. The company’s technology is being applied to multiple therapeutic cargos, including antibodies, enzymes, proteins, and nucleic acids.
- Alector continues to pursue ADP037-ABC, its brain-penetrant anti-amyloid beta antibody in AD, and ADP050-ABC, its GCase enzyme replacement therapy in Parkinson’s disease, both of which are enabled by ABC.
Corporate News
- Giacomo Salvadore, M.D., was appointed to Alector’s executive leadership team, assuming the role of Chief Medical Officer. Dr. Salvadore is an established industry executive physician and leader with more than 15 years of experience leading neurology-focused clinical development functions. He joined Alector in 2023 as Senior Vice President of Clinical Development and has a deep knowledge and understanding of the company’s pipeline and strategic priorities.
First Quarter 2025 Financial Results
Revenue. Collaboration revenue for the quarter ended March 31, 2025, was
R&D Expenses. Total research and development expenses for the quarter ended March 31, 2025, were
G&A Expenses. Total general and administrative expenses for the quarter ended March 31, 2025, were
Net Loss. For the quarter ended March 31, 2025, Alector reported a net loss of
Cash Position. Cash, cash equivalents, and investments were
2025 Guidance. Management is reiterating its guidance for the year ending 2025. The company continues to anticipate collaboration revenue to be between
About Alector
Alector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of genetically validated programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as frontotemporal dementia, Alzheimer’s disease, and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding our business plans, business strategy, product candidates, blood-brain barrier technology platform, research and preclinical pipeline, planned and ongoing preclinical studies and clinical trials, anticipated timing of and detail regarding release of data for INFRONT-3, expected milestones, expectations of our collaborations, expectations of our interactions with regulatory authorities, and financial and cash guidance. Such statements are subject to numerous risks and uncertainties, including but not limited to risks and uncertainties as set forth in Alector’s Quarterly Report on Form 10-Q filed on May 8, 2024, with the Securities and Exchange Commission (“SEC”), as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector’s forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law.
| Selected Consolidated Balance Sheet Data (in thousands) | ||||||
| March 31, | December 31, | |||||
| 2025 | 2024 | |||||
| Cash, cash equivalents, and marketable securities | $ | 354,551 | $ | 413,397 | ||
| Total assets | 408,303 | 468,303 | ||||
| Total current liabilities (excluding deferred revenue) | 87,923 | 101,396 | ||||
| Deferred revenue (including current portion) | 192,158 | 195,832 | ||||
| Total liabilities | 313,693 | 341,503 | ||||
| Total stockholders’ equity | 94,610 | 126,800 | ||||
| Consolidated Statement of Operations Data (in thousands, except share and per share data) | ||||||||||
| Three Months Ended March 31, | ||||||||||
| 2025 | 2024 | |||||||||
| Collaboration revenue | $ | 3,674 | $ | 15,893 | ||||||
| Operating expenses: | ||||||||||
| Research and development | 33,641 | 45,167 | ||||||||
| General and administrative | 14,728 | 14,434 | ||||||||
| Total operating expenses | 48,369 | 59,601 | ||||||||
| Loss from operations | (44,695 | ) | (43,708 | ) | ||||||
| Other income, net | 4,224 | 7,636 | ||||||||
| Loss before income taxes | (40,471) | (36,072) | ||||||||
| Income tax expense | — | 7 | ||||||||
| Net loss | $ | (40,471 | ) | $ | (36,079 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.41 | ) | $ | (0.38 | ) | ||||
| Shares used in computing net loss per share basic and diluted | 99,398,200 | 93,810,177 | ||||||||
Alector Contacts:
Alector
Katie Hogan
202-549-0557
katie.hogan@alector.com
Argot Partners (media)
David Rosen
646-461-6387
alector@argotpartners.com
Argot Partners (investors)
Laura Perry
212-600-1902
alector@argotpartners.com
FAQ
What were Alector's (ALEC) key financial results for Q1 2025?
When will Alector (ALEC) report topline data for the INFRONT-3 Phase 3 trial?
What is Alector's (ALEC) cash runway projection?
What is Alector's (ALEC) 2025 financial guidance?
What progress has Alector (ALEC) made in its Alzheimer's disease program?
